Clinical Trial Update: Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors [Phase 2]

View source ↗

Summary

This entry reports the completion of a Phase 2 clinical trial evaluating ABT-126 for mild to moderate Alzheimer's disease in patients taking stable doses of ace…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ABT-126

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED